Treatment of osteoporosis with nitrogen-containing bisphosphonates in Endocrinology Clinic Târgu Mureş during 2004-2008

Written by Kun Imre Zoltán, Szántó Zsuzsanna, Stoica Krisztina, Balázs József, Năsălean Anisie, Gliga Camelia

We studied the efficacy and tolerability of alendronate, risedronate (both administered weekly, 18 months) and ibandronate (monthly, 12 months), following-up the prevention of fragility fractures and adverse events at 235 patients with osteoporosis. Fragility fractures appeared in 5.3% out of alendronate, 2.02% out of risedronate, and in none of ibandronate group. Digestive disturbances were observed in 35.7%, 7.0% and 2.5% after alendronate, risedronate and ibandronate, respectively. 10.7% and 3.0% of patients renounced to alendronate and risedronate, respectively, and nobody to the ibandronate therapy. All three bisphosphonates were efficient for the treatment of osteoporosis. Ibandronate and risedronate had less gastrointestinal complications as alendronate. The best compliance was observed for ibandronate, which can be attributed to its rare, mild adverse effects and monthly administration.


Keywords: alendronate, risedronate, ibandronate, fragility fracture, digestive adverse events.

Print   Email